Related Experiment Video
Updated: Jul 14, 2026
08:57
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
Published on: March 26, 2015
Emerging therapies for MS.
1UCSF MS Center, University of California-San Francisco, 350 Parnassus Street, San Francisco, CA 94117, USA. emmanuelle.waubant@ucsf.edu
Revue Neurologique
|July 4, 2007
Summary
New multiple sclerosis (MS) treatments target immune balance, B cells, and inflammation. Promising therapies include intravenous and oral agents, with future approaches focusing on neuroprotection and CNS repair.
Area of Science:
- Immunology
- Neuroscience
- Pharmacology
Background:
- Traditional immune modulators for multiple sclerosis (MS) primarily target T cells.
- Interferon beta (IFNB) and glatiramer acetate (GA) are examples of established MS therapies.
- Recent advancements reveal novel therapeutic strategies beyond T cell modulation.
Purpose of the Study:
- To review emerging therapeutic strategies for multiple sclerosis (MS).
- To discuss treatments targeting general immune balance, specific immune cells (B cells), and inflammatory cell migration to the central nervous system (CNS).
- To highlight ongoing phase III trials and future directions including neuroprotection and CNS repair.
Main Methods:
- Review of current and emerging multiple sclerosis (MS) therapeutic strategies.
- Analysis of treatments targeting immune modulation, B cell responses, and inflammatory cell migration.
- Examination of phase III trial data for novel agents and future therapeutic directions.
Main Results:
- Novel strategies encompass broad immune modulation, specific inhibition of B cell responses (antibody-dependent and independent), and prevention of inflammatory cell CNS migration.
- Several promising agents are in phase III trials for relapsing-remitting MS, including intravenous (alemtuzumab, rituximab) and oral therapies (FTY720, fumaric acid, laquinomod).
- Emerging approaches are also investigating neuroprotection and CNS repair.
Conclusions:
- The therapeutic landscape for MS is rapidly evolving beyond T cell-centric approaches.
- New treatments offer targeted immune modulation and improved delivery methods.
- Future MS therapies aim to address neuroprotection and CNS repair, offering comprehensive disease management.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:19Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...